Walgreens delivered $39.0B in revenue for Q3 2025, growing year-over-year. However, it posted a net loss of $175M due to prior year gains not recurring and higher tax expenses. Adjusted EPS dropped to $0.38 as cost savings were offset by weaker retail sales and lower equity earnings.

Walgreens Boots Alliance posted a net loss of $2.9 billion in Q2 2025 due to $4.2 billion in non-cash impairment charges. Revenue grew 4.1% YoY, with notable gains in the U.S. Healthcare segment, though front-end retail softness and legal settlements negatively impacted results.

Walgreens Boots Alliance reported a 7.5% increase in sales to $39.5 billion for the first quarter of fiscal year 2025. However, the company experienced a loss per share of $0.31, although adjusted EPS was $0.51. The company is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.

Walgreens Boots Alliance reported a 6.0% increase in fourth-quarter sales to $37.5 billion, but experienced a net loss of $3.0 billion, or $3.48 per share, compared to a net loss of $180 million, or $0.21 per share in the year-ago quarter. Adjusted EPS was $0.39, a 40.8% decrease on a constant currency basis. The company announced a footprint optimization program targeting approximately 1,200 closures over the next three years.

Walgreens Boots Alliance reported a 2.6% increase in sales to $36.4 billion for the third quarter of fiscal year 2024. However, adjusted EPS decreased by 36.6% to $0.63, impacted by lower sale-leaseback gains and a challenging U.S. retail environment. The company is lowering its fiscal year 2024 adjusted EPS guidance to $2.80 to $2.95.

Walgreens Boots Alliance (WBA) announced its fiscal 2024 second quarter results, revealing a 6.3% increase in sales to $37.1 billion, but a net loss of $5.9 billion due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Adjusted EPS increased by 3.4% to $1.20. The company narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35.

Walgreens Boots Alliance reported a 10.0% increase in sales to $36.7 billion, but experienced a net loss of $67 million and a decrease in adjusted EPS to $0.66. The company is maintaining its fiscal 2024 adjusted EPS guidance of $3.20 to $3.50.

Walgreens Boots Alliance reported a Q4 sales increase of 9.2% year-over-year to $35.4 billion, but experienced a net loss of $180 million. Adjusted EPS was $0.67, down 18.0% on a constant currency basis. The company is implementing cost reduction measures and focusing on accelerating profitability in the U.S. Healthcare segment.

Walgreens Boots Alliance (WBA) reported an 8.6% increase in sales to $35.4 billion for the third quarter of fiscal year 2023. Adjusted EPS increased by 3.3% to $1.00. However, the company revised its full-year adjusted EPS guidance to $4.00 - $4.05 due to consumer market trends and lower COVID-19 demand. WBA is taking immediate actions to improve profitability, including raising its Transformational Cost Management Program target to $4.1 billion.

Walgreens Boots Alliance reported a 3.3% increase in sales to $34.9 billion, but experienced a decrease in EPS to $0.81 and adjusted EPS to $1.16, impacted by lower COVID-19 vaccine and testing volumes. The company invested in VillageMD's acquisition of Summit Health and maintained its full-year adjusted EPS guidance.

Walgreens Boots Alliance reported first quarter fiscal 2023 results with sales decreasing 1.5 percent year-over-year to $33.4 billion. Adjusted EPS decreased 30.8 percent to $1.16. The company is maintaining full-year adjusted EPS guidance and raising full-year sales guidance.

Walgreens Boots Alliance reported Q4 sales of $32.4 billion, a 5.3% decrease year-over-year. The company's loss per share was $0.48, while adjusted EPS decreased by 31.8% to $0.80. Despite these declines, Walgreens is raising its U.S. Healthcare fiscal 2025 sales target and expects low-teens adjusted EPS growth in fiscal year 2025 and beyond.

Walgreens Boots Alliance reported a decrease in third quarter sales by 4.2 percent to $32.6 billion. EPS decreased 73.8 percent to $0.33, while adjusted EPS decreased 30.0 percent to $0.96. The company is maintaining its full year adjusted EPS guidance of low-single digit growth.

Walgreens Boots Alliance reported a 3.0% increase in sales from continuing operations to $33.8 billion and an adjusted EPS increase of 25.9% to $1.59 in the second quarter of fiscal 2022. The company is maintaining its full-year adjusted EPS guidance of low-single digit growth.

Walgreens Boots Alliance reported strong first quarter results for fiscal year 2022, exceeding expectations across all business segments. Key drivers included COVID-19 vaccinations and testing, strong U.S. retail comparable sales, and a rebound in International segment sales and profitability. The company raised its full year adjusted EPS guidance.

Walgreens Boots Alliance reported strong Q4 2021 results, exceeding expectations with a 12.8% increase in sales to $34.3 billion and adjusted EPS of $1.17, reflecting robust growth in both the International and United States segments. The company surpassed its COVID-19 vaccination goal, administering 13.5 million vaccinations during the quarter, and achieved over $2 billion in annual cost savings through its Transformational Cost Management Program.

Walgreens Boots Alliance reported a strong third quarter, exceeding expectations with sales increasing by 12.1% to $34.0 billion and adjusted EPS growing by 83.4% to $1.51. The company raised its full-year guidance to around 10% growth in constant currency adjusted EPS from continuing operations.

Walgreens Boots Alliance reported a 4.6% increase in sales to $32.8 billion for the second quarter of fiscal 2021. EPS increased 10.9% to $1.19, and the company raised its full-year EPS guidance.

Walgreens Boots Alliance reported a 5.7% increase in sales to $36.3 billion for the first quarter of fiscal 2021. However, the company experienced a loss per share of $0.36, primarily due to a $1.73 per share charge from its equity earnings in AmerisourceBergen. Adjusted EPS decreased by 11.2% to $1.22. The company maintained its guidance of low single-digit growth in adjusted earnings per share for fiscal 2021.

Walgreens Boots Alliance reported a 2.3% increase in sales to $34.7 billion for the fourth quarter of fiscal year 2020. However, operating income decreased by 26.0% to $650 million, and EPS decreased by 42.8% to $0.43, impacted by COVID-19. The company introduced fiscal 2021 guidance of low single-digit growth in adjusted EPS at constant currency rates.

Walgreens Boots Alliance reported a challenging third quarter due to the COVID-19 pandemic, which significantly impacted sales and operating income. The company took actions to mitigate these impacts and accelerated investments in strategic priorities, increasing its annual cost savings target. While sales saw a slight increase, the company reported an operating loss due to impairment charges in Boots UK.

Walgreens Boots Alliance reported a 3.7% increase in sales to $35.8 billion and an EPS of $1.07. Adjusted EPS decreased 7.3% to $1.52. The company was on track to maintain fiscal 2020 guidance before the COVID-19 pandemic.

Walgreens Boots Alliance reported a 1.6% increase in sales to $34.3 billion, but experienced a 24.8% decrease in net earnings to $845 million and a 19.8% decrease in EPS to $0.95. The company maintained its guidance of roughly flat growth in fiscal 2020 adjusted EPS on a constant currency basis.